
|Videos|January 9, 2014
Tivantinib and Regorafenib for the Treatment of Liver Cancer
Author(s)Richard S. Finn, MD
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.
Advertisement
Clinical Pearls
Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses the use of tivantinib and regorafenib for the treatment of patients with liver cancer.
- Tivantinib is in phase III development for liver cancer
- A phase II study comparing tivantinib to placebo showed no dramatic benefit in all-comers
- An analysis showed high MET expression was associated with worse prognosis, and high MET patients saw benefit from tivantinib versus low MET
- Regorafenib has shown activity in colorectal cancer and GIST
- A phase II study of regorafenib demonstrated provocative survival data for patients who have progressed on sorafenib
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Oncology Update January 2026: New Horizons in Precision Medicine
2
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
3
Building Better ADCs for GI Cancers: Targets, Timing, and Toxicities
4
CD47 Expression Serves as Predictive Biomarker for HER2+ Breast Cancer
5



















